Jung-min Lee, MD, on Ovarian Cancer: Study Results on Checkpoint Kinase Inhibitors

2016 ESMO Congress
Tweet this page

Jung-min Lee, MD, of the National Cancer Institute, discusses findings of a phase II study of the cell cycle checkpoint kinase inhibitors LY2606368 and prexasertib monomesylate monohydrate in sporadic high-grade serous and germline BRCA mutation-associated ovarian cancer. (Abstract 855O)

Advertisement

Advertisement



Advertisement